Education
About Us
Working with TipRanks
Follow Us
Australian Clinical Labs Ltd (AU:ACL)
ASX:ACL
Total Valuation
Australian Clinical Labs Ltd has a market cap or net worth of AU$413.27M. The enterprise value is AU$854.06M.
Market CapAU$413.27M
Enterprise ValueAU$854.06M
Share Statistics
Australian Clinical Labs Ltd has 192,220,870 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding192,220,870
Owned by Insiders0.04%
Owned by Institutions―
Financial Efficiency
Australian Clinical Labs Ltd’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 39.51%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)39.51%
Return on Capital Employed (ROCE)0.76
Revenue Per Employee151.28K
Profits Per Employee6.62K
Employee Count4,900
Asset Turnover1.29
Inventory Turnover30.11
Valuation Ratios
The current PE Ratio of Australian Clinical Labs Ltd is 15.9. Australian Clinical Labs Ltd’s PEG ratio is 0.39.
PE Ratio15.9
PS Ratio0.71
PB Ratio3.09
Price to Fair Value3.09
Price to FCF3.03
Price to Operating Cash Flow2.68
PEG Ratio0.39
Income Statement
In the last 12 months, Australian Clinical Labs Ltd had revenue of 741.27M and earned 32.43M in profits. Earnings per share was 0.17.
Revenue741.27M
Gross Profit270.86M
Operating Income270.86M
Pretax Income48.18M
Net Income32.43M
EBITDA81.36M
Earnings Per Share (EPS)0.17
Cash Flow
In the last 12 months, operating cash flow was 164.57M and capital expenditures -7.88M, giving a free cash flow of 156.69M billion.
Operating Cash Flow164.57M
Free Cash Flow156.69M
Free Cash Flow per Share0.82
Dividends & Yields
Australian Clinical Labs Ltd pays an annual dividend of AU$0.09, resulting in a dividend yield of 4.6%
Dividend Per ShareAU$0.09
Dividend Yield4.6%
Payout Ratio71.43%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.96
52-Week Price Change-38.03%
50-Day Moving Average2.65
200-Day Moving Average2.67
Relative Strength Index (RSI)24.77
Average Volume (3m)867.30K
Important Dates
Australian Clinical Labs Ltd upcoming earnings date is Aug 26, 2026, TBA (Confirmed).
Last Earnings DateFeb 15, 2026
Next Earnings DateAug 26, 2026
Ex-Dividend Date―
Financial Position
Australian Clinical Labs Ltd as a current ratio of 0.55, with Debt / Equity ratio of 301.27%
Current Ratio0.55
Quick Ratio0.48
Debt to Market Cap0.08
Net Debt to EBITDA3.31
Interest Coverage Ratio14.75
Taxes
In the past 12 months, Australian Clinical Labs Ltd has paid 15.36M in taxes.
Income Tax15.36M
Effective Tax Rate0.32
Enterprise Valuation
Australian Clinical Labs Ltd EV to EBITDA ratio is 9.80, with an EV/FCF ratio of 4.57.
EV to Sales1.08
EV to EBITDA9.80
EV to Free Cash Flow4.57
EV to Operating Cash Flow4.36
Balance Sheet
Australian Clinical Labs Ltd has AU$23.14M in cash and marketable securities with AU$453.61M in debt, giving a net cash position of -AU$430.47M billion.
Cash & Marketable SecuritiesAU$23.14M
Total DebtAU$453.61M
Net Cash-AU$430.47M
Net Cash Per Share-AU$2.24
Tangible Book Value Per ShareAU$0.04
Margins
Gross margin is 28.62%, with operating margin of 36.54%, and net profit margin of 4.37%.
Gross Margin28.62%
Operating Margin36.54%
Pretax Margin6.50%
Net Profit Margin4.37%
EBITDA Margin10.98%
EBIT Margin9.17%
Analyst Forecast
The average price target for Australian Clinical Labs Ltd is AU$2.38, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetAU$2.38
Price Target Upside8.18% Upside
Analyst ConsensusHold
Analyst Count4
Revenue Growth Forecast6.73%
EPS Growth Forecast37.16%